Literature DB >> 12774055

IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs.

G E Georges1, R Storb, J Maciej Zaucha, A G Taranova, T Gooley, R A Nash.   

Abstract

A dog model of stable mixed hematopoietic chimerism was established in which leukocyte-antigen-identical littermates receive nonmyeloablative total body irradiation before hematopoietic cell transplantation and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. Unmodified donor lymphocyte infusion (DLI) into stable mixed chimeras failed to increase donor chimerism, while DLI from donors sensitized to recipient minor-histocompatibility antigens promptly converted all recipients to complete donor chimerism. This established a model for studying approaches to enhance the graft-versus-host (GVH)-effect, a potential surrogate for graft-versus-leukemia activity. We asked if interleukin-2 (IL-2) given after unmodified DLI could result in reliable conversion to complete donor chimerism. IL-2, 4 x 10(5) IU/kg/day, was administered to six mixed chimeric dogs for 14 days. Four dogs received unmodified DLI with IL-2. At 20-40 weeks after DLI, all dogs remained mixed chimeras. For the two recipients of IL-2 only, mixed chimerism also remained unchanged. These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774055     DOI: 10.1038/sj.bmt.1704046

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Mixed chimerism renders residual host dendritic cells incapable of alloimmunization of the marrow donor in the canine model of allogeneic marrow transplantation.

Authors:  Steven L Rosinski; Scott S Graves; Deborah A Higginbotham; Rainer Storb
Journal:  Chimerism       Date:  2015-10-02

2.  Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Scott S Graves; Maura H Parker; Rainer Storb
Journal:  ILAR J       Date:  2018-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.